SCHEMBL3010282

SCHEMBL3010282

COc1cc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3)n2)cc(OC)c1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.38
IGF1R P08069 1/20 0.36
ALK Q9UM73 1/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 1/20 0.35
AVPR1B P47901 1/20 0.34
LIPE Q05469 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
HCRTR1 O43613 5/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HCRTR2 O43614 4/20 0.34
PDE5A O76074 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
CHRM4 P08173 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013307 0.92 KDM4E (0.40) ALDH1A1SMN1; SMN2KDM4EAVPR1BHCRTR1
SCHEMBL3013530 0.91 RAB9A (0.36) SMN1; SMN2KDM4EAVPR1BLIPEF2RL3
SCHEMBL3020517 0.89 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2GAAMAPK1KDM4E
SCHEMBL3006609 0.89 AVPR1B (0.40) SMN1; SMN2AVPR1BLIPELMNAMAPT
SCHEMBL3016319 0.88 LIPE (0.40) AVPR1BLIPECHRM4
SCHEMBL3115792 0.88 GBA1 (0.39) ALDH1A1SMN1; SMN2GAAMAPK1F2RL3
SCHEMBL3020251 0.87 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2GAAMAPK1F2RL3
SCHEMBL3011419 0.87 MAPT (0.40) ALDH1A1SMN1; SMN2GAAMAPK1F2RL3
SCHEMBL3010886 0.87 TP53 (0.39) ALDH1A1SMN1; SMN2GAAMAPK1F2RL3
SCHEMBL3015985 0.87 LIPE (0.37) AVPR1BLIPECHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CSNK1D 1182/4885IGF1R 2929/4885ALK 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.